Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 5/2013

01-10-2013 | Testis and Penile Cancer (M Manoharan and J Sheinfeld, Section Editors)

Late Relapse of Testis Cancer

Authors: Yaron Ehrlich, Eli Rosenbaum, Jack Baniel

Published in: Current Urology Reports | Issue 5/2013

Login to get access

Abstract

Most relapses of germ-cell tumors occur within 2 years of initial treatment. In 2 % to 4 % of patients, relapse may occur later. The retroperitoneum is the primary site of late relapses, and alpha-fetoprotein is the predominant marker. These tumors are highly resistant to chemotherapy. Surgical resection is the preferred treatment. If the recurrent disease is inoperable, salvage chemotherapy may be instituted, followed by resection of the residual disease.
Literature
1.
Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981;41(9 Pt 1):3275–80.PubMed
2.
3.
Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–40.PubMedCrossRef
4.
Bosl GJ, Gluckman R, Geller NL, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol. 1986;4(10):1493–9.PubMed
5.
6.
•• Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995;13(5):1170–6. Indiana University was the first to report late relapse as a distinct clinical entity.PubMed
7.
Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med. 1987;317:1688–91.PubMedCrossRef
8.
Stenman UH, Alfthan H, Ranta T, Vartiainen E, Jalkanen J, Seppala M. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab. 1987;64:730–6.PubMedCrossRef
9.
Catalona WJ, Vaitukaitis JL, Fair WR. Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: conversion to negative with testosterone administration. J Urol. 1979;122:126–8.PubMed
10.
Garnick MB. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med. 1980;303:1177.PubMed
11.
Braunstein GD, Thompson R, Gross S, Soares JR. Marijuana use does not spuriously elevate serum human chorionic gonadotropin levels. Urology. 1985;25:605–6.PubMedCrossRef
12.
Bell H. Alpha-fetoprotein and carcinoembryonic antigen in patients with primary liver carcinoma, metastatic liver disease, and alcoholic liver disease. Scand J Gastroenterol. 1982;17:897–903.PubMedCrossRef
13.
Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974;34(suppl):1510–5.PubMedCrossRef
14.
Masopust J, Kithier K, Rádl J, Koutecký J, Kotál L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer. 1968;3:364–73.PubMedCrossRef
15.
Kitau MJ, Grint PC, Heath RB, Chard T. Serum alphafetoprotein levels in subjects infected with hepatitis B virus. J Med Virol. 1988;26:437–42.PubMedCrossRef
16.
Schefer H, Mattmann S, Joss RA. Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. Ann Oncol. 1998;9:667–72.PubMedCrossRef
17.
Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23(28):6999–7004.PubMedCrossRef
18.
George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21(1):113–22.PubMedCrossRef
19.
Mukhtar S, Beatty J, Agrawal S, et al. Germ cell tumour: late recurrence after 43 years. Ann R Coll Surg Engl. 2011;93:e24–6.PubMedCrossRef
20.
• Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173(3):824–9. A contemporary population based study of late relapse.PubMedCrossRef
21.
Oldenburg J, Alfsen GC, Waehre H, et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer. 2006;94:820–7.PubMedCrossRef
22.
Oldenburg J, Martin JM, Fosså SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol. 2006;24:5503–11.PubMedCrossRef
23.
Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8(1):41–7.PubMedCrossRef
24.
Ravi R, Oliver RT, Ong J, et al. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol. 1997;80(4):647–52.PubMedCrossRef
25.
Kuczyk MA, Bokemeyer C, Kollmannsberger C, et al. Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center based experience. World J Urol. 2004;22(1):55–9.PubMedCrossRef
26.
Michael H, Lucia J, Foster RS, et al. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol. 2000;24(2):257–73.PubMedCrossRef
27.
Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002;95(3):520–30.PubMedCrossRef
28.
Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.PubMedCrossRef
29.
Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29:719–25.PubMedCrossRef
30.
Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200–8.PubMedCrossRef
31.
Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146–54.PubMed
32.
Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103:241–9.PubMedCrossRef
33.
Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21:1296–301.PubMedCrossRef
34.
Sturgeon JF, Moore MJ, Kakiashvili DM, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol. 2011;59:556–62.PubMedCrossRef
35.
Nolan L, Wheater M, Kirby J, et al. Late relapse (>2 years) on surveillance in stage I non-seminomatous germ cell tumours; predominant seminoma only histology. BJU Int. 2010;106:1648–51.PubMedCrossRef
36.
Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27:2122–8.PubMedCrossRef
37.
Nicolai N, Miceli R, Necchi A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol. 2010;58:912–8.PubMedCrossRef
38.
Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23(36):9290–4.PubMedCrossRef
39.
Ehrlich Y, Beck SDW, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol. 2010;21:1846–50.PubMedCrossRef
40.
Loehrer Sr PJ, Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135(6):1183–9.PubMed
41.
Leibovitch I, Foster RS, Ulbright TM, et al. Adult primary pure teratoma of the testis. The Indiana experience. Cancer. 1995;75:2244–50.PubMedCrossRef
42.
Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol. 2003;163:2477–84.PubMedCrossRef
43.
van Echten J, van der Vloedt WS, van de Pol M, et al. Comparison of the chromosomal pattern of primary testicular nonseminomas and residual mature teratomas after chemotherapy. Cancer Genet Cytogenet. 1997;99:59–67.PubMedCrossRef
44.
Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study group. J Clin Oncol. 2001;19(10):2647–57.PubMed
45.
Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82(7):1343–51.PubMedCrossRef
46.
Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–76.PubMedCrossRef
47.
Debono DJ, Heilman DK, Einhorn LH, et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15:1455–64.PubMed
48.
Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. J Clin Oncol. 2010;28:519–2.PubMedCrossRef
49.
Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a post-chemotherapy retroperitoneal lymph node dissection needed following complete remission? J Clin Oncol. 2010;28:531–6.PubMedCrossRef
50.
•• Sharp DS, Carver BS, Eggener SE, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008;26:5524–9. Contemporary late relapse series from MSKCC emphasizing the importance of complete surgical excision of late relapse masses.PubMedCrossRef
51.
Schmoll HJ. SouchonR, Krege S, et al.: European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15(9):1377–99.PubMedCrossRef
52.
Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int. 2006;98:353–8.PubMedCrossRef
53.
•• Lorch A, Rick O, Wündisch T, et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol. 2010;184:168–73. Late relapse not suitable for surgery is chemoresistant and response to high dose chemotherapy is usually not durable.PubMedCrossRef
54.
Aparicio J. Garcia del Muro X, Maroto P, et al.: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003;14(6):867–72.PubMedCrossRef
55.
Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293–300.PubMedCrossRef
56.
Muramaki M, Hara I, Miyake H, et al. Clinical study of six cases showing late relapse of germ cell tumors. Int J Urol. 2005;12(9):855–8.PubMedCrossRef
57.
Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998;58(19):4260–3.PubMed
58.
Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14(6):873–80.PubMedCrossRef
59.
Mayer F, Wermann H, Albers P, et al. Histopathological and molecular features of late relapses in non-seminomas. BJU Int. 2011;107:936–43.PubMedCrossRef
60.
Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10(7):2368–78.PubMedCrossRef
Metadata
Title
Late Relapse of Testis Cancer
Authors
Yaron Ehrlich
Eli Rosenbaum
Jack Baniel
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Urology Reports / Issue 5/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0355-4

Other articles of this Issue 5/2013

Current Urology Reports 5/2013 Go to the issue

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Management Options for Women with Uterine Prolapse Interested in Uterine Preservation

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Myofascial Trigger Points of the Pelvic Floor: Associations with Urological Pain Syndromes and Treatment Strategies Including Injection Therapy

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Latissimus Dorsi Detrusor Myoplasty to Restore Voiding in Patients with an Acontractile Bladder – Fact or Fiction?

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Laparoendoscopic Single-Site Surgery in Kidney Surgery: Clinical Experience and Future Perspectives